Description

YK-11 ZPHC — 10 mg (100 tablets × 10 mg)

---

Product Overview

YK-11 ZPHC represents a significant advancement in research compounds, offering a unique mechanism of action distinct from traditional selective androgen receptor modulators. This product is manufactured by ZPHC, a pharmaceutical-grade facility, and is supplied as 100 film-coated, scored tablets each containing 10 mg of pure YK-11. The tablets are designed for precise dosing and are easily divisible for research protocols requiring 5 mg increments.

Product Overview

YK-11 ZPHC represents a significant advancement in research compounds, offering a unique mechanism of action distinct from traditional selective androgen receptor modulators. This product is manufactured by ZPHC, a pharmaceutical-grade facility, and is supplied as 100 film-coated, scored tablets each containing 10 mg of pure YK-11. The tablets are designed for precise dosing and are easily divisible for research protocols requiring 5 mg increments.

Product Overview

YK-11 ZPHC represents a significant advancement in research compounds, offering a unique mechanism of action distinct from traditional selective androgen receptor modulators. This product is manufactured by ZPHC, a pharmaceutical-grade facility, and is supplied as 100 film-coated, scored tablets each containing 10 mg of pure YK-11. The tablets are designed for precise dosing and are easily divisible for research protocols requiring 5 mg increments.

YK-11 is a synthetic, steroidal compound classified as a partial agonist of the androgen receptor, a mechanism that has been documented in peer-reviewed research. Its differentiating characteristic lies in its dual-action pathway, as it is believed to upregulate follistatin expression, which inhibits myostatin—a protein that naturally limits muscle growth. This dual mechanism makes YK-11 a compound of significant interest in the field of muscle biology and endocrinology.

---

Key Features and Specifications

Pharmaceutical-Grade Manufacturing

• Manufactured by ZPHC, a facility known for adherence to stringent quality control standards

• Each batch is subject to rigorous analytical testing, including HPLC and LC-MS verification

• Independently lab-tested to confirm purity exceeding 99%

• Comprehensive heavy-metal and microbiological clearance protocols are followed

Product Presentation

• Supplied in tamper-evident, sealed blisters to maintain product integrity

• Each tablet is film-coated and scored for accurate dosage division

• 100 tablets per box, each containing 10 mg of active YK-11 (1000 mg total)

• Packaging includes scratch-code authenticity verification system

Formulation and Dosing Guidelines

• Recommended research dosage: 5–15 mg daily

• Suggested cycle length for research purposes: 6–8 weeks

• Scored tablets allow precise splitting for 5 mg dosing protocols

• Exhibits excellent oral bioavailability

---

Mechanism of Action

Research indicates that YK-11 functions as a gene-selective partial agonist of the androgen receptor (AR). Unlike full agonists such as dihydrotestosterone (DHT), YK-11 does not induce the physical interaction between the amino-terminal domain (NTD/AF1) and the ligand-binding domain (LBD/AF2), known as the N/C interaction, which is required for full AR transactivation. This unique binding profile is believed to contribute to its tissue-selective effects.

Furthermore, YK-11 has been shown to accelerate nuclear translocation of the androgen receptor and upregulate follistatin mRNA expression in vitro. Follistatin, in turn, is a potent inhibitor of myostatin, a negative regulator of skeletal muscle growth. This dual mechanism—direct AR agonism combined with myostatin suppression—distinguishes YK-11 from other compounds in its class.

In vitro studies have demonstrated that YK-11 induces myogenic differentiation and enhances osteoblast proliferation and differentiation, suggesting it may have applications in both muscle and bone biology research.

---

Quality Assurance

Each batch of YK-11 ZPHC undergoes comprehensive quality control procedures:

• Purity Verification: HPLC analysis confirms >99% purity

• Identity Confirmation: LC-MS analysis verifies compound identity

• Impurity Profiling: Systematic screening for synthesis byproducts

• Heavy Metal Testing: Compliance with pharmaceutical standards

• Microbiological Testing: Clearance for bacterial and fungal contamination

For researchers requiring documentation, batch-specific Certificates of Analysis (COA) are available upon request.

---

Storage and Handling

• Store in a cool, dry environment away from direct sunlight

• Optimal storage conditions: room temperature (15–25°C) in the original packaging

• Protect from moisture and humidity

• Keep blisters sealed until time of use

• Do not use beyond the expiration date printed on the packaging

---

Frequently Asked Questions (FAQs)

Q1: What is the primary mechanism of action for YK-11?

YK-11 is a synthetic, steroidal compound that functions as a partial agonist of the androgen receptor (AR) and a myostatin inhibitor. It binds to the AR without inducing full transcriptional activation and significantly increases follistatin expression, which inhibits myostatin—a negative regulator of muscle growth.

Q2: What is the recommended research dosage for YK-11?

Based on available research protocols, the typical dosage range is 5–15 mg per day, administered orally. The scored tablets allow for precise splitting to accommodate 5 mg dosing. Cycle lengths in research settings typically range from 6 to 8 weeks.

Q3: What are the documented purity specifications for this product?

Each batch of YK-11 ZPHC is tested to confirm purity exceeding 99% through HPLC analysis, with identity verification via LC-MS and comprehensive impurity profiling.

Q4: What are the potential off-target effects of YK-11?

Potential off-target effects documented in research literature include testosterone suppression through negative feedback on the hypothalamic-pituitary-gonadal axis, hepatotoxicity at higher doses, and androgenic side effects. A 2025 study in rats also suggested potential impacts on hippocampal neurochemistry.

Q5: How does YK-11 differ from other selective androgen receptor modulators?

YK-11 is unique among SARMs due to its dual mechanism of action: it acts as a partial AR agonist while simultaneously inhibiting myostatin through follistatin upregulation. This dual mechanism potentially allows for muscle growth beyond what would be achievable through AR agonism alone.

Q6: Can YK-11 be stacked with other research compounds?

Research protocols have documented stacking YK-11 with compounds such as RAD-140 and Ligandrol. The synergistic effect is believed to leverage YK-11’s myostatin-inhibiting properties alongside other compounds’ direct AR agonistic activity. Dosages in such protocols typically range from 5–10 mg for YK-11 and 10–20 mg for the secondary compound.

Q7: What quality control procedures are applied to this product?

YK-11 ZPHC undergoes comprehensive quality control including HPLC purity verification (>99%), LC-MS identity confirmation, heavy-metal testing, microbiological clearance, and batch-specific documentation with Certificates of Analysis.

Q8: Is YK-11 approved for human use?

No. YK-11 is a research compound not approved by regulatory authorities such as the FDA for human consumption. It is supplied for in vitro and in vivo research purposes only. Products are for research use only and not for human use.

Q9: What are the storage requirements for YK-11?

Store at room temperature (15–25°C) in the original packaging away from direct sunlight, moisture, and humidity. The film-coated tablets should remain in sealed blisters until use to maintain stability and integrity.

Q10: What authentication measures are included with this product?

Each box of YK-11 ZPHC includes a scratch-code authenticity verification system on the tamper-evident packaging, allowing researchers to verify the product’s origin and confirm it has not been tampered with.

---

Research Applications

YK-11 is of interest in several research contexts:

Muscle Biology

• Investigation of myostatin inhibition pathways

• Study of androgen receptor-mediated transcription

• Research into muscle cell differentiation and hypertrophy

Bone Biology

• Examination of osteoblastic differentiation and proliferation

• Research into androgen receptor signaling in bone tissue

Endocrinology

• Study of selective androgen receptor modulation

• Investigation of tissue-selective anabolic effects

---

Safety and Disclaimer

Important Notice: This product is supplied for research purposes only. It is not intended for human consumption, therapeutic use, or as a dietary supplement. All researchers must consult with appropriate institutional review boards and follow relevant guidelines for the handling and use of research compounds.

Potential users should be aware that research suggests YK-11 may suppress natural testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis. Hepatotoxicity has been documented in high-dose protocols, and long-term safety has not been established due to limited clinical research.

---

References

1. Kanno Y, et al. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biol Pharm Bull. 2013;36(9):1460-5. 

2. MedKoo Scientific. YK11 Product Data. CAS#: 1370003-76-1. 

3. BenchChem Technical Support Center. YK-11 Experimental Protocols. December 2025. 

4. The Mechanisms of Anabolic Steroids, Selective Androgen Receptor Modulators and Myostatin Inhibitors. KCI Journal. 2025. 

5. Evaluating Purerawz SARMs: What Lab Documentation Reveals. 2025. 

6. Swolverine. YK-11 and RAD-140 Stack: Build Lean Mass Faster. 2025. 

7. Meds Safety. YK-11 Side Effects, Dosage, Pros, and Cons. 2023. 

---

Secure ordering and tracked worldwide shipping available.

Visit Anabolic Steroids Online Shop to place your order today.